Healthcare Industry News:  Endoscopic Vessel Harvesting 

Devices Acquisitions

 News Release - January 3, 2006

Datascope Acquires Endoscopic Vessel Harvesting Business From Ethicon, Inc.

MONTVALE, NEW JERSEY--(Healthcare Sales & Marketing Network)--Jan 3, 2006 -- Datascope Corp. (NasdaqNM:DSCP ) announced today that it has closed on its acquisition of the ClearglideŽ Endoscopic Vessel Harvesting product line of the Ethicon CardioVations division on the previously announced terms, with a portion of the purchase price payable upon the closing of the acquisition of Guidant Corp. by Johnson & Johnson. Ethicon, Inc. is a Johnson & Johnson company.

Endoscopic Vessel Harvesting devices enable less-invasive techniques for the harvesting of suitable vessels for use in conjunction with coronary artery bypass grafting. Endoscopic Vessel Harvesting procedures have been steadily replacing traditional open vessel harvesting since the early 1990s. The "open" vessel harvesting procedures can cause significant pain and discomfort for patients during the recovery period and leave a scar that may run the full length of the patient's leg or forearm. In addition, the large incision that is required in an open vessel harvesting procedure is associated with a high rate of wound complications including dehiscence, hematoma and infection. Randomized and non-randomized clinical trials comparing Endoscopic Vessel Harvesting performed with the Clearglide vessel harvesting system to traditional open vessel harvesting techniques have demonstrated the endoscopic approach to be associated with fewer wound complications than the traditional open method.

The vessel harvesting product line will be integrated into Datascope's Cardiac Assist Division ("Cardiac Assist"). Cardiac Assist is a leader in counterpulsation therapy and markets its products to cardiac surgeons, the physicians who perform coronary artery bypass graft surgery. Datascope believes that the Endoscopic Vessel Harvesting products are an attractive addition to Cardiac Assist's product portfolio and will benefit from Cardiac Assist's marketing, sales, clinical education / training, and new product development capabilities.

"We look forward to the opportunity to manufacture and market the Clearglide devices," commented Terry Gunning, President of Cardiac Assist. "We believe that Datascope's strength in the cardiovascular surgery call point and commitment to technology innovation will enable us to increase Clearglide sales and expand the overall Endoscopic Vessel Harvesting market."

Datascope's counterpulsation therapy is widely used to provide temporary assistance to the heart in a variety of critical care settings, including cardiogenic shock, high-risk coronary angioplasty / stenting procedures, and coronary artery bypass surgery. Counterpulsation refers to inflation and deflation of an intra-aortic balloon synchronized with the heartbeat in a manner that provides a two-fold assist to the beating heart: increasing its oxygen supply while decreasing its oxygen demand, an intervention that often restores the supply and demand balance necessary for the patient's recovery.

This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties cannot be predicted or quantified and are outside our control, particularly the risk that Datascope will not be able to increase Clearglide sales and expand the overall vessel harvesting market.

Datascope Corp. is a diversified medical device company that manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. Datascope's news releases and other company information can be found on the company's website, http://www.datascope.com.


Source: Datascope

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.